Bradley Boeve, MD
Neurology · Rochester, MNNPI 1053397216
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,200 of the $6,950 with a category attached, or 60.4%. 3 manufacturers reported payments, led by Eli Lilly at 39.6% of the total.
Across 4 payments — averaging $1737.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- GE HealthCare$2K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$2K
Across 26 payments — averaging $21,226 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$282K
- Johnson & Johnson$147K
- GE HealthCare$74K
- Biogen$49K
What the payments were for
- Consulting fees$2,75040%
- Speaking & faculty fees$4,20060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $2,750 |
| GE HealthCare | 2 | $2,400 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $1,800 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIZAMYL$2,400
How this compares
$6,950 in reported general payments places this provider in the 85th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Armodafinil | 14 | $2,054 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $1,231 |
| Rivastigmine | 12 | $1,082 |
| Galantamine ErGalantamine Hbr | 13 | $706 |
| Memantine Hcl | 19 | $513 |
| Donepezil Hcl | 22 | $272 |
| Clonazepam | 14 | $182 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Wolfgang SingerRochester$128K
- Ronald PetersenRochester$126K
- Partha GhoshRochester$121K
- Eoin FlanaganRochester$55K
- Keith CoffmanRochester$24K
- Igal MirmanRochester$18K
- P James DyckRochester$17K
- Suresh KotagalRochester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.